Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systems Analyses of Immune Response to Seasonal Influenza Vaccine
NCT04025580Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2019
- Primary completion
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Fluzone Trivalent, influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (uv, formaldehyde inactivated), influenza virus vaccine, split virion in influenza, sponsored by National Institute of Allergy and Infectious Diseases. Started Oct 2019; status: completed.
02
Drugs
Fluzone Trivalentinfluenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (uv, formaldehyde inactivated)influenza virus vaccine, split virion
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04025580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04025580.